Batun farashin magunguna ke kara daukar hankali a Amurka, domin duk da matsin lambar da Shugaba Donald Trump ke yi na a rage farashi, masana’antar magunguna ta shirya ƙara farashin fiye da magunguna 350 a shekarar 2026. Rahoton da kamfanin bincike 3 Axis Advisors ya fitar ya nuna cewa karin farashin zai shafi manyan magunguna irin su allurar rigakafin COVID, RSV da shingles, da kuma maganin cutar daji Ibrance. Matsakaicin karin farashin yana kusan 4%, kamar yadda aka gani a bara.
Sai dai duk da haka, wasu kamfanonin sun rage farashin wasu magunguna, ciki har da kamfanin Boehringer Ingelheim, wanda ya rage farashin Jardiance da wasu magungunan da suka shafi ciwon suga da sama da kashi 40%, musamman bayan gwamnatin Amurka ta shiga yarjejeniyar rage farashin magungunan da tsofaffi ke amfani da su ta Medicare.
Duk da yarjejeniyoyi da gwamnati ke yi da kamfanoni irin su Pfizer, GSK, Sanofi, Novartis da Boehringer, har yanzu ana ganin karin farashin ya fi rinjaye. Masana sun ce waɗannan yarjejeniyoyi ba su tabo tushen matsalar tsadar magani sosai ba, domin har yanzu Amurkawa na biyan mafi tsada idan aka kwatanta da ƙasashe masu ci gaba. Kamfanonin sun ce karin farashin na da muhimmanci don su ci gaba da gudanar da bincike, kirkire-kirkire da kuma gyaran tsarin su.
